Off-Label Communication: Industry Opposes Exclusion Of Phase II Data From US FDA’s Guidance

Revised draft guidance about scientific information on unapproved uses (SIUU) of medical products is “impermissibly paternalistic and overly restrictive of scientific speech,” MIWG says.